Literature DB >> 22030039

The use of misoprostol in termination of second-trimester pregnancy.

Chen-Ju Lin1, Shu-Chin Chien, Chih-Ping Chen.   

Abstract

Misoprostol, a synthetic prostaglandin E1 analog, is initially used to prevent peptic ulcer. The initial US Food and Drug Administration-approved indication in the product labeling is the treatment and prevention of intestinal ulcer disease resulting from nonsteroidal anti-inflammatory drugs use. In recent two decades, misoprostol has approved to be an effective agent for termination of pregnancy in various gestation, cervical ripening, labor induction in term pregnancy, and possible management of postpartum hemorrhage. For the termination of second-trimester pregnancy using the combination of mifepristone and misoprostol seems to have the highest efficacy and the shortest time interval of abortion. When mifepristone is not available, misoprostol alone is a good alternative. Misoprostol, 400 μg given vaginally every 3-6 hours, is probably the optimal regimen for second-trimester abortion. More than 800 μg of misoprostol is likely to have more side effects, especially diarrhea. Although misoprostol can be used in women with scarred uterus for termination of second-trimester pregnancy, it is recommended that women with a scarred uterus should receive lower doses and do not double the dose if there is no initial response. It is also important for us to recognize the associated teratogenic effects of misoprostol and thorough consultation before prescribing this medication to patients regarding these risks, especially when failure of abortion occurs, is needed.
Copyright © 2011. Published by Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22030039     DOI: 10.1016/j.tjog.2011.07.003

Source DB:  PubMed          Journal:  Taiwan J Obstet Gynecol        ISSN: 1028-4559            Impact factor:   1.705


  6 in total

1.  Misoprostol versus High Dose Oxytocin and Laminaria in Termination of Pregnancy in Second Trimester Pregnancies.

Authors:  Azin Alavi; Minoo Rajaei; Malihe Amirian; Lili Nikuee Ghazvini
Journal:  Electron Physician       Date:  2013-11-01

2.  Prostaglandin E2 receptor 3 signaling is induced in placentas with unexplained recurrent pregnancy losses.

Authors:  Yao Ye; Aurelia Vattai; Nina Ditsch; Christina Kuhn; Martina Rahmeh; Sven Mahner; Myriam Ripphahn; Roland Immler; Markus Sperandio; Udo Jeschke; Viktoria von Schönfeldt
Journal:  Endocr Connect       Date:  2018-04-26       Impact factor: 3.335

3.  Does feticide shorten termination duration in second trimester pregnancy terminations?

Authors:  Aytek Şık; Sedat Bilecan; Serkan Kumbasar; Yaşam Kemal Akpak; Yilda Arzu Aba
Journal:  Afr Health Sci       Date:  2019-03       Impact factor: 0.927

4.  Analysis on Medication Rules of Chinese Medicinal Herb Formulae in Uterine Subinvolution Treatment Based on Data Mining.

Authors:  Jianghe Luo; Ming Yang; Yuling Liu; Xinrui Han; Wei Yue
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-31       Impact factor: 2.629

5.  How risky are second trimester clandestine abortions in Cameroon: a retrospective descriptive study.

Authors:  Elie Nkwabong; Robinson Enow Mbu; Joseph Nelson Fomulu
Journal:  BMC Womens Health       Date:  2014-09-09       Impact factor: 2.809

6.  The use of misoprostol for cervical priming prior to hysteroscopy: a systematic review and analysis.

Authors:  Ying Hua; Wenwen Zhang; Xiaoli Hu; Ansu Yang; Xueqiong Zhu
Journal:  Drug Des Devel Ther       Date:  2016-09-06       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.